|
|
|
|
|
Methadone
drug data and news
Methadone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Methadone | ||
| Brand Names/Synonyms | Adanon; Adanon hydrochloride; Adolan; Algidon; Algolysin; Algovetin; Althose hydrochloride; Amidon; Amidone; Biscuits; Butalgin; CCRIS 3320; DL-Methadone hydrochloride; DRG-0023; Depridol; Diaminon; Diaminon hydrochloride; Dollies; Dolly; Dolofin hydrochloride; Dolohepton; Dolophin; Dolophin hydrochloride; Dolophine; Dolophine HCL; Fenadon; Fenadone; Heptadon; Heptadone; Heptanon; Ketalgin; Ketalgin hydrochloride; Mecodin; Medicine; Mephenon; Meth; Methadon; Methadone; Methadone HCL; Methadone HCL Intensol; Methadone M; Methadone hydrochloride; Methadone hydrochloride dl-; Methadose; Methaquaione; Miadone; Moheptan; Phenadone; Phenadone hydrochloride; Physeptone; Polamidon; Polamidone; Racemic methadone; Racemic methadone hydrochloride; Tussol:; Westadone; dl-Methadone; (+/-)-Methadone; (+/-)-Methadone hydrochloride; (+/-)-Tussal | ||
| Indication | For the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence,pain | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Methadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. | ||
| Mechanism Of Action | Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Methadone's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Methadone has a unique affinity for the NMDA brain receptor. It is believed that NMDA (N-methyl-D-aspartic acid) may regulate psychic dependence and tolerance by exhibiting opioid antagonist-like activity. | ||
| Methadone News (When available) |
Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ... 07 Mar 2006 Taxotere® and Novantrone® Sequence Evaluated as Initial ... Feb 22, 2006 Recurrence-Free Survival Improved with Taxotere® Compared to ... Feb 23, 2006 Neoadjuvant Herceptin® plus Taxotere® Promising in Early Breast ... Feb 24, 2006 Cell Genesys Reports Encouraging Follow-Up Survival Data From ... Feb 27, 2006 GVAX® Vaccine Promising for Hormone-Refractory Prostate Cancer Feb 28, 2006 Spectrum presents new satraplatin prostate cancer data Feb 28, 2006 Cell Genesys Reports Encouraging Follow-Up Survival Data From ... Feb 27, 2006 Spectrum Pharmaceuticals announces Presentation of New Satraplatin ... Feb 27, 2006 ASCO Prostate: Intermittent Chemotherapy Controls Androgen ... Feb 28, 2006 Treatment “Holidays� Effective in Hormone-Refractory Prostate ... Mar 1, 2006 Cytogen's Quadramet Helps Lower PSA Feb 27, 2006 GPC Biotech Presents New Satraplatin Clinical Data from ... Feb 27, 2006 Xeloda Expands Options in Adjuvant Treatment of Breast Cancer ... Feb 21, 2006 Information on knee pain, breast cancer drugs and protecting bones Feb 22, 2006 Pharmion Corporation Announces New Satraplatin Clinical Data From ... Feb 27, 2006 Drug May Help Curb Breast Cancer Feb 22, 2006 GPC Biotech Presents New Satraplatin Clinical Data From ... Feb 27, 2006 Breast Cancer Drugs Limit Post-Surgery Recurrence Feb 22, 2006 Breast meds limit recurrence Feb 23, 2006 Trails to detect effective breast cancer drugs that reduces ... Feb 23, 2006 Sanofi-Aventis' Battered Charm Mar 1, 2006 MRI Contrast Agent Enhances Chemotherapy's Cancer Killing Feb 15, 2006 Positive Findings From Clinical Studies of QUADRAMET(R) in ... Feb 27, 2006 Cell Genesys gives promising prostate cancer trial update Feb 28, 2006 YM's Breast-Cancer Drug is Fast-Tracked Feb 13, 2006 YM BioSciences breast cancer drug fast-tracked by FDA Feb 14, 2006 American Pharmaceutical Partners and American BioScience Announce ... Feb 14, 2006 Sanofi to Introduce Acomplia as Diet Pill This Year (Update3) Feb 23, 2006 YM BioSciences reports second quarter 2006 operational and ... Feb 10, 2006 GPC says satraplatin well tolerated in Phase I Feb 27, 2006 Adjuvant Docetaxel More Effective Than Vinorelbine for Early ... Feb 23, 2006 Cancer, AIDS drugs may get cheaper after Budget Feb 22, 2006 Clean-up sparks lifesaving plan Feb 20, 2006 Sanofi expects Acomplia launch in 06; profits up Feb 24, 2006 Agency discloses '04 medicine deaths Jan 31, 2006 Instead of spending $150,000 on a house, I'll be spending it on my ... Feb 18, 2006 UPDATE 1-Novacea files for $75 million IPO Feb 10, 2006 Lung Cancer Drug Pipeline Update Lists All 243 Drugs for Lung ... Feb 16, 2006 Cell Therapeutics: hoping for a rich performance Feb 9, 2006 IP Chemotherapy Encouraged for Ovarian Cancer Feb 13, 2006 YM BioSciences receives FDA fast track designation for tesmilifene ... Feb 13, 2006 Study Confirms Better Quality of Life with Paraplatin® than ... Feb 7, 2006 Genomic Health Announces Fourth Quarter and Year-end 2005 ... Feb 13, 2006 Nereus Pharmaceuticals Appoints Dr. Gary Shearman Chairman of the ... Feb 15, 2006 Favrille Reports Fourth Quarter and Year End 2005 Financial ... Feb 9, 2006 Favrille Reports Fourth Quarter and Year End 2005 Financial ... Feb 10, 2006 Genomic Health Announces Fourth Quarter and Year-end 2005 ... Feb 13, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Narcotics; Antitussives; Analgesics; Opiate Agonists; ATC:N02AC52; ATC:N07BC02; ATC:R05DA06 | ||
| Absorption | Not Available | ||
| Interactions | Interactions for Methadone: Interaction with Pentazocine Patients who are addicted to heroin or who are on the methadone maintenance program may experience withdrawal symptoms when given pentazocine. Interaction with Rifampin The concurrent administration of rifampin may possibly reduce the blood concentration of methadone. The mechanism by which rifampin may decrease blood concentrations of methadone is not fully understood although enhanced microsomal drug-metabolized enzymes may influence drug disposition. Interaction with Monoamine Oxidase (MAO) Inhibitors Therapeutic doses of meperidine have precipitated severe reactions in patients concurrently receiving monoamine oxidase inhibitors or those who have received such agents within 14 days. Similar reactions thus far have not been reported with methadone; but if the use of methadone is necessary in such patients, a sensitivity test should be performed in which repeated small incremental doses are administered over the course of several hours while the patient's condition and vital signs are under careful observation. Interaction with Other Central-Nervous-Systern Depressants Methadone should be used with caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics, tricyclic antidepressants, and other CNS depressants (including alcohol). Respiratory depression, hypotension, and profound sedation or coma may result. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-dimethylamino-4,4-diphenyl-heptan-3-one | ||
| Chemical Formula | C21H27NO | ||
| Molecular Weight | 309.445 g/mol | ||
| Smiles String | CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2 | ||
| Melting Point | 235.0°C | ||
| Water Solubility | 48.5 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 5.458 | ||
| Isoelectric Point | 8.94 | ||
| Biotransformation | Not Available | ||
| Half Life | 24-36 hrs. | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Methadone.html http://www.rxlist.com/cgi/generic/methdone.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00485 | ||
| CAS Registry Number | 76-99-3 | ||
| KEGG Compound ID | C07163 | ||
| PubChem ID | SID:149416 | ||
| PharmGKB ID | PA450401 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2247698 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |